MAM
Ignite Mudra wins creative duties of Cyberoam
MUMBAI: Ignite Mudra has won the creative duties of Elitecore‘s unified threat management brand, Cyberoam.
The account size is estimated to be Rs 80-100 million.
There was a formal pitch process wherein a clutch of agencies were invited to present a strategic direction for this new brand.
Ignite Mudra head Sudarshan Banerjee said, “We are delighted to be associated with Elitecore, which is an established brand for IT products and software solutions in Network Security, Telecommunications and Access Gateway. We are excited about our association with a new age product launch like this. This is largely an uncharted territory where the rules of the game are not defined.”
Cyberoam senior VP–product management Abhilash Sonwane, pointed to the robust strategic direction that the agency brought on the table as the main reason for handing over the assignment.
Sonwane added, “Given Ignite Mudra‘s impressive credentials, we were keen to see how the agency would approach a brand launch like ours. The team demonstrated a very thorough understanding of the challenges and the approach to overcome them. This is very crucial for us as we have largely operated in the B2B segment so far.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
